Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient

University of Miami's Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Clinical Cancer Research (Impact Factor: 8.72). 08/2011; 17(17):5559-61. DOI: 10.1158/1078-0432.CCR-10-2051
Source: PubMed


The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others. Clin Cancer Res; 17(17); 5559-61. (C)2011 AACR.

Download full-text


Available from: Stefan Gluck
  • Source
    • "CTC monitoring during trastuzumab treatment might point out patients who will do well. Now studies have shown that dual HER2 blockade by combining two or three agents with nonoverlapping mechanisms of action, improves cell death and tumor shrinkage in HER2 positive tumors.[7374] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating tumor cell (CTC) measurement in peripheral blood of patients with breast cancer offers prognostic information. In this review, we will try to identify evidence that could be used for prognosis, predictive power to draw this tool to clinical utility. We reviewed 81 manuscripts, and categorized those in discovery datasets, prognostic factors in metastatic breast cancer, identification of clinical utility in early breast cancer and in novel approaches. With each patient responding differently to chemotherapy, more efficient markers would improve clinical outcome. Current CTC diagnostic techniques use epithelial markers predominantly; however, the most appropriate method is the measurement of circulating DNA. It has been hypothesized that micrometastasis occurs early in the development of tumors. That implies the presence of CTCs in nonmetastatic setting. The origin of stimulus for malignant transformation is yet unknown. The role of microenvironment as a stimulus is also being investigated. It has been shown that CTCs vary in numbers with chemotherapy. The markers, which are followed-up in the primary tumors, are also being studied on the CTCs. There is discordance of the human epidermal growth factor receptor-2 status between the primary tumor and CTCs. This review summarizes our current knowledge about the CTCs. With genetic profiling and molecular characterization of CTCs, it is possible to overcome the diagnostic difficulties. Evidence for clinical utility of CTC as prognostic and predictive marker is increasing. Appropriate patient stratification according to CTC determination among other tests, would make personalized cancer therapy more feasible.
    Full-text · Article · Jun 2014 · Journal of Carcinogenesis
  • Source
    • "Because many solid tumors overexpress human epidermal growth factor receptor 2 (HER2) and carcinoembryonic antigen (CEA), they are good targets for immunotherapy [25,26]. Both HER2 and CEA are cell surface markers involved in cell-mediated immunity (CMI) and antibody-dependent cell-mediated cytotoxicity (ADCC) [25,27]. In a series of preclinical studies, we have shown that when inserted into Ad vectors or delivered via DNA-EP, codon-optimized versions of the CEA and HER2 complementary DNAs (cDNAs) are capable of inducing potent T- and B-cell immune responses and break tolerance to self in mice and nonhuman primates [13,28,29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: DNA electroporation has been demonstrated in preclinical models to be a promising strategy to improve cancer immunity, especially when combined with other genetic vaccines in heterologous prime-boost protocols. We report the results of 2 multicenter phase 1 trials involving adult cancer patients (n=33) with stage II-IV disease. Patients were vaccinated with V930 alone, a DNA vaccine containing equal amounts of plasmids expressing the extracellular and trans-membrane domains of human HER2, and a plasmid expressing CEA fused to the B subunit of Escherichia coli heat labile toxin (Study 1), or a heterologous prime-boost vaccination approach with V930 followed by V932, a dicistronic adenovirus subtype-6 viral vector vaccine coding for the same antigens (Study 2). The use of the V930 vaccination with electroporation alone or in combination with V932 was well-tolerated without any serious adverse events. In both studies, the most common vaccine-related side effects were injection site reactions and arthralgias. No measurable cell-mediated immune response (CMI) to CEA or HER2 was detected in patients by ELISPOT; however, a significant increase of both cell-mediated immunity and antibody titer against the bacterial heat labile toxin were observed upon vaccination. V930 vaccination alone or in combination with V932 was well tolerated without any vaccine-related serious adverse effects, and was able to induce measurable immune responses against bacterial antigen. However, the prime-boost strategy did not appear to augment any detectable CMI responses against either CEA or HER2. Study 1 -, NCT00250419; Study 2 -, NCT00647114.
    Full-text · Article · Mar 2013 · Journal of Translational Medicine
  • Source
    • "One potential strategy is to combine multiple drugs that hit biologically important pathways at different places. Such a combinatorial strategy 175 will definitely increase efficacy, but we must choose wisely which combinations to pursue in future clinical trials. We believe that more thorough preclinical testing may help us make more informed decisions on which combinations should be brought forward into the clinic, especially when it is unlikely that we will be able to empirically test every possible combination. "
    [Show abstract] [Hide abstract]
    ABSTRACT: For many years, the medical treatment of breast cancer was reliant solely on cytotoxic chemotherapy. However, over the past twenty years, treatment has evolved to a more target-directed approach. We now employ tailored therapy based on the presence or absence of receptors for estrogen, progesterone, and human epidermal growth factor 2 (HER2). We expect this trend to continue, as agents that use novel approaches to target HER2, as well as targeting different portions of the HER signaling pathway, are in various stages of development. Notably, pertuzumab, a humanized monoclonal antibody that binds to a different domain of the extracellular portion of the HER2 receptor than trastuzumab, was recently approved for use, as was lapatinib, a small-molecule tyrosine kinase inhibitor. Patients with triple negative breast cancer, particularly those with the BRCA mutation, have more limited treatment options and carry a worse prognosis than those who are hormone receptor positive. However, recent data has shown that PARP inhibitors may have significant anti-tumor effect in those with this subtype of breast cancer. Novel agents that inhibit mTOR, PI3K, the insulin-like growth factor, heat shock protein 90, and histone deacetylase have shown promise in phase I-III trials and offer exciting new possibilities for the treatment of this often fatal disease. As we are presented with an ever increasing number of treatment options, the timing and combinations of therapeutic agents used becomes ever more complex in the age of personalized care, but we are hopeful that ultimately this will lead to improved patient outcomes.
    Full-text · Article · Jan 2013 · Journal of Cancer
Show more